TSTickerStarGet alerts

TPST 10-Q filed 2026-11-13 | Key takeaways

TPST filed its 10-Q; the most relevant disclosure change is added Acquired in-process research and development expense: The company began presenting acquired in-process research and development expense as a separate line item in the condensed consolidated statements of operations starting Q1 2026, with $22.2 million expensed for the nine months ended September 30, 2026 related.

Share this story

Key takeaways

  • Net loss improved to $3.6 million in Q3 2026 from $5.2 million in Q2 2026, with net loss per share of $0.21 versus $0.34 in the prior quarter.

  • R&D expenses decreased significantly to $0.2 million in Q3 2026 from $1.8 million in Q2 2026 as the company shifted focus to CAR-T programs following the Erigen Asset Acquisition.

  • Cash and cash equivalents declined to $0.9 million as of September 30, 2026 from $7.7 million at December 31, 2025, with substantial doubt about the company's ability to continue as a going concern.

  • The company entered into a $25-50 million Equity Line of Credit with Lincoln Park Capital in August 2026 and completed a $2.5 million September 2026 Private Placement.

  • Subsequent events include exercise of 3.1 million pre-funded warrants in October 2026, vendor settlement reducing a $0.7 million liability to $0.2 million, and expiration of the Rights Agreement on October 10, 2026.

  • The company exercised its option to license Senlang's in vivo CAR-T technology outside Greater China on November 11, 2026, requiring initial license fee of RMB 3.0 million plus annual maintenance fees of $10-14 million.

  • Nasdaq compliance issues remain with an extension granted until November 16, 2026 for stockholders' equity requirement and a new bid price deficiency notice received November 4, 2026.

Key metrics

Net loss - Q3 2026Q3 2026
$3.629 millionUp from $3.511 million in Q3 2025
Net loss - Nine months 2026Nine months ended September 30, 2026
$36.569 millionUp from $22.241 million in nine months 2025
Net loss per share - Q3 2026Q3 2026
$0.21Improved from $0.79 in Q3 2025 due to increased share count
Net loss per share - Nine months 2026Nine months ended September 30, 2026
$2.54Improved from $5.71 in nine months 2025
Cash and cash equivalentsSeptember 30, 2026
$0.897 millionDown from $7.707 million at December 31, 2025
Research and development - Q3 2026Q3 2026
$0.207 millionDown from $0.570 million in Q3 2025
General and administrative - Q3 2026Q3 2026
$2.616 millionDown from $3.027 million in Q3 2025
Acquired in-process R&D - Nine months 2026Nine months ended September 30, 2026
$22.180 millionFirst time presented as separate line item; $0 in nine months 2025

Disclosure changes

  • Acquired in-process research and development expense

    The company began presenting acquired in-process research and development expense as a separate line item in the condensed consolidated statements of operations starting Q1 2026, with $22.2 million expensed for the nine months ended September 30, 2026 related to the Erigen Asset Acquisition.

    This represents a significant new expense category resulting from the February 2026 Erigen Asset Acquisition and is material to understanding the company's financial performance.
  • Financing costs related to equity line of credit

    The company recognized $0.8 million of financing costs related to the equity line of credit during Q3 2026, consisting of $0.66 million for the fair value of commitment shares issued to Lincoln Park and $0.15 million of issuance costs.

    This represents a new expense category associated with the Lincoln Park Equity Line of Credit entered into in August 2026.
  • Going concern disclosure

    The company states there is substantial doubt about its ability to continue as a going concern for 12 months from the date the financial statements were available to be issued, as existing cash of $0.9 million will fund operations for less than 12 months.

    The company's liquidity position remains critical with only $0.9 million in cash and multiple financing activities not expected to fund operations for 12 months.
  • Related party transactions with Factor Bioscience

    The company entered into a new $5.0 million per year 2026 Factor MSA and Work Order on September 22, 2026, replacing the prior arrangement. Factor agreed to permanently waive the first $2.1 million payable under the prior Work Order. Dr. Angel, CEO, is the majority owner of Factor.

    Significant related party transactions with the company's CEO and principal stockholder require ongoing monitoring.
  • Senlang collaboration agreements

    The company entered into a Product Development and Collaboration Agreement with Senlang in July 2026 for IIT activities in China and an Exclusive Option and License Agreement in September 2026 for Senlang's in vivo CAR-T technology outside Greater China, with the option exercised on November 11, 2026.

    New strategic collaboration for development of in vivo CAR-T candidates with potential future royalty and milestone obligations.
  • Nasdaq compliance

    The company received a Nasdaq deficiency notice regarding minimum stockholders' equity on May 19, 2026, with an extension granted until November 16, 2026. A new bid price deficiency notice was received on November 4, 2026.

    Continued Nasdaq listing risk with potential delisting if compliance is not regained.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow TPST in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert